SLC5A5 and Hashimoto thyroiditis: Previous studies had shown that peptide-based assays gave incongruent results for NIS-aAb or PDS-aAb prevalence, ranging from 0–10% in controls, to 0–84% in Graves’ disease, and up to 0–97.5% in Hashimoto’s thyroiditis [46].